SCHEMBL6656896

SCHEMBL6656896

CCCOc1cc(C2=NN(Cc3ccc(NC(=O)CCN4CCSCC4)cc3)C(=O)SC2)ccc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 3/20 0.49
PDE4D Q08499 3/20 0.49
PDE4B Q07343 3/20 0.49
PDE4A P27815 2/20 0.49
PDE4C Q08493 2/20 0.49
PDE3B Q13370 2/20 0.49
PDE3A Q14432 2/20 0.49
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
MCHR1 Q99705 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6659043 0.94 MET (0.51) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6660664 0.94 PDE4D (0.49) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6662196 0.93 MET (0.50) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6841946 0.93 PDE4B (0.52) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6655950 0.93 PDE4D (0.49) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6656422 0.93 PDE4D (0.49) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6654931 0.92 PDE4D (0.49) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6655621 0.91 MET (0.48) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6837708 0.91 PDE4B (0.56) METPDE4DPDE4BPDE4APDE4C
SCHEMBL6844144 0.90 MET (0.59) METPDE4DPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B MET 4676/4885PDE4D 12/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.